Top Markets
Coin of the day
Nanobiotix S.A. Nanobiotix S.A.

Nanobiotix S.A.

NANO
Clasificación en acciones #5950
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on... Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Precio por acción
$45.79
Capitalización bursátil
$2.33B
Cambio (1 día)
11.43%
Cambio (1 año)
408.10%
País
FR
Comercio Nanobiotix S.A. (NANO)

Categoría

Ganancias de Nanobiotix S.A. (NANO)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Nanobiotix S.A., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Nanobiotix S.A. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
$5.27B -
US
$1.95B -
NL
$-4.02B -
AU
$-3.09B -
US
- -
CH